Advertisement
Screener

NANOVIRICIDES, INC. (NNVC) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

NANOVIRICIDES, INC. Net Income (Loss) Available to Common Stockholders, Basic

NANOVIRICIDES, INC. (NNVC) reported Net Income (Loss) Available to Common Stockholders, Basic of -$8.56 million for the 12-month period ending 2018-06-30, per its 10-K filed 2018-10-12.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2018-10-12

  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-06-30 was -$1.65M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$2.11M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2017-12-31 was -$2.80M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2017-09-30 was -$2.01M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$8.56M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$10.30M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$10.72M.
  • NANOVIRICIDES, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$2.20M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 9 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 12 month
2018-06-30-$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-12
-$3.76M
derived: sum of 2 quarters · filed 2018-10-12
-$6.56M
derived: sum of 3 quarters · filed 2018-10-12
-$8.56M
10-K · filed 2018-10-12
2018-03-31-$2.11M
10-Q · filed 2018-05-21
-$4.91M
derived: sum of 2 quarters · filed 2018-05-21
-$6.91M
10-Q · filed 2018-05-21
-$9.47M
derived: sum of 4 quarters · filed 2018-10-12
2017-12-31-$2.80M
10-Q · filed 2018-02-20
-$4.80M
10-Q · filed 2018-02-20
-$7.36M
derived: sum of 3 quarters · filed 2018-10-12
-$10.50M
derived: sum of 4 quarters · filed 2018-10-12
2017-09-30-$2.01M
10-Q · filed 2017-11-14
-$4.56M
derived: sum of 2 quarters · filed 2018-10-12
-$7.70M
derived: sum of 3 quarters · filed 2018-10-12
-$9.25M
derived: sum of 4 quarters · filed 2018-10-12
2017-06-30-$2.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-12
-$5.70M
derived: sum of 2 quarters · filed 2018-10-12
-$7.24M
derived: sum of 3 quarters · filed 2018-10-12
-$10.30M
10-K · filed 2018-10-12
2017-03-31-$3.14M
10-Q · filed 2018-05-21
-$4.69M
derived: sum of 2 quarters · filed 2018-05-21
-$7.75M
10-Q · filed 2018-05-21
-$9.40M
derived: sum of 4 quarters · filed 2018-10-12
2016-12-31-$1.55M
10-Q · filed 2018-02-20
-$4.61M
10-Q · filed 2018-02-20
-$6.26M
derived: sum of 3 quarters · filed 2018-10-12
-$11.25M
derived: sum of 4 quarters · filed 2018-10-12
2016-09-30-$3.06M
10-Q · filed 2017-11-14
-$4.71M
derived: sum of 2 quarters · filed 2018-10-12
-$9.70M
derived: sum of 3 quarters · filed 2018-10-12
-$12.48M
derived: sum of 4 quarters · filed 2018-10-12
2016-06-30-$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-12
-$6.64M
derived: sum of 2 quarters · filed 2018-10-12
-$9.42M
derived: sum of 3 quarters · filed 2018-10-12
-$10.72M
10-K · filed 2018-10-12
2016-03-31-$4.99M
10-Q · filed 2017-05-15
-$7.77M
derived: sum of 2 quarters · filed 2017-05-15
-$9.07M
10-Q · filed 2017-05-15
-$9.99M
derived: sum of 4 quarters · filed 2017-09-28
2015-12-31-$2.78M
10-Q · filed 2017-02-14
-$4.08M
10-Q · filed 2017-02-14
-$5.00M
derived: sum of 3 quarters · filed 2017-09-28
-$5.25M
derived: sum of 4 quarters · filed 2017-09-28
2015-09-30-$1.31M
10-Q · filed 2016-11-14
-$2.22M
derived: sum of 2 quarters · filed 2017-09-28
-$2.48M
derived: sum of 3 quarters · filed 2017-09-28
-$4.36M
derived: sum of 4 quarters · filed 2017-09-28
2015-06-30-$917.71K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28
-$1.17M
derived: sum of 2 quarters · filed 2017-09-28
-$3.05M
derived: sum of 3 quarters · filed 2017-09-28
-$2.20M
10-K · filed 2017-09-28
2015-03-31-$251.02K
10-Q · filed 2016-05-10
-$2.13M
derived: sum of 2 quarters · filed 2016-05-10
-$1.28M
10-Q · filed 2016-05-10
-$1.28M
10-Q · filed 2015-05-15
-$8.28M
derived: sum of 4 quarters · filed 2016-09-16
2014-12-31-$1.88M
10-Q · filed 2016-02-09
-$1.03M
10-Q · filed 2016-02-09
-$8.03M
derived: sum of 3 quarters · filed 2016-09-16
-$6.71M
derived: sum of 4 quarters · filed 2016-09-16
2014-09-30$851.70K
10-Q · filed 2015-11-09
-$6.15M
derived: sum of 2 quarters · filed 2016-09-16
-$4.82M
derived: sum of 3 quarters · filed 2016-09-16
-$6.19M
derived: sum of 4 quarters · filed 2016-09-16
2014-06-30-$7.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-16
-$5.68M
derived: sum of 2 quarters · filed 2016-09-16
-$7.04M
derived: sum of 3 quarters · filed 2016-09-16
-$13.60M
10-K · filed 2016-09-16
2014-03-31$1.32M
10-Q · filed 2015-05-15
-$39.64K
derived: sum of 2 quarters · filed 2015-05-15
-$6.60M
10-Q · filed 2015-05-15
2013-12-31-$1.36M
10-Q · filed 2015-02-25
-$7.93M
10-Q · filed 2015-02-25
2013-06-30-$8.88M
10-K · filed 2015-09-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30